European Patent Office to Grant Merck KGaA, Darmstadt, Germany’s Patent Application for CRISPR Technology
Download PDF Read more
Matters of legal in nature including licensing, intellectual property, and lawsuits.
Download PDF Read more
Patent application covers integration of an external DNA sequence into the chromosome of eukaryotic cells using CRISPR Related patent application recently awarded in Australia; similar patents pending in other countries, favorable outcomes anticipated Billerica, Massachusetts, August 3, 2017 — MilliporeSigma today announced that the European Patent Office (EPO) has issued a “Notice of Intention to Grant” for MilliporeSigma’s... Read more
Molecular and Sample Barcoding IP Portfolio Bolsters Agilent’s Leadership Position in NGS Target Enrichment Solutions IP Portfolio Aimed at Improving Accuracy and Sensitivity of NGS Detection SANTA CLARA, Calif.–(BUSINESS WIRE)–Jul. 24, 2017– Agilent Technologies Inc. (NYSE: A) (“Agilent”) today announced that it has acquired the molecular and sample barcoding patent portfolios of Population Genetics Technologies (“Population... Read more
Molecular and Sample Barcoding IP Portfolio Bolsters Agilent’s Leadership Position in NGS Target Enrichment Solutions IP Portfolio Aimed at Improving Accuracy and Sensitivity of NGS Detection SANTA CLARA, Calif., July 24, 2017 Agilent Technologies Inc. (NYSE: A) (“Agilent”) today announced that it has acquired the molecular and sample barcoding patent portfolios of Population Genetics Technologies... Read more
Molecular and Sample Barcoding IP Portfolio Bolsters Agilent’s Leadership Position in NGS Target Enrichment Solutions IP Portfolio Aimed at Improving Accuracy and Sensitivity of NGS Detection SANTA CLARA, Calif.–(BUSINESS WIRE)–Jul. 24, 2017– Agilent Technologies Inc. (NYSE: A) (“Agilent”) today announced that it has acquired the molecular and sample barcoding patent portfolios of Population Genetics Technologies (“Population... Read more
Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more
Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more
Adult Thy1-EYFP H line mouse, in vivo (cranial window). Excitatory pyramidal neurons in Layer 5 partly express EYFP. Courtesy of Dr. Masahiro Fukuda and Prof. Haruo Kasai, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan Advances in multiphoton microscopy instruments and technology are leading to unique insights... Read more
NEW YORK, NY, June 29, 2017 – Enzo Biochem Inc. (NYSE: ENZ) reported today that a federal judge for the U.S. District Court for the District of Delaware has entered an order in the actions entitled Enzo Life Sciences, Inc. v. Gen-Probe Incorporated, Enzo Life Sciences, Inc. v. Hologic, Inc., Enzo Life Sciences, Inc. v. Roche Molecular... Read more
Wednesday, July 12, 2017: 9 AM PST / 12 PM EST / 5 PM BST Advances in multiphoton microscopy instruments and technology are leading to unique insights into the cellular world. From live-cell imaging to three-dimensional reconstructions of cells and their organelles, researchers are taking full advantage of the power of multiphoton microscopy to enhance... Read more